newsfilter
← Latest News
GlobeNewswire·

Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting

BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that it will participate in an oral presentation highlighting the